Why Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading Today

NEW YORK (TheStreet) -- Endocyte  (ECYT) plummeted approximately 25% in after-hours trading on Tuesday after the biopharmaceutical company announced Merck  (MRK), through a subsidiary, would no longer pursue development of vintafolide, aka Vynfinit.

Endocyte said it has regained worldwide rights to the ovarian cancer drug and will evaluate Vynfinit "for future development opportunities."

Endocyte's stock plummeted on May 2 when the drug failed in a Phase III study. For more on that, read TheStreet's Adam Feuerstein's story here.

Must Read: Endocyte Falls on Ovarian Cancer Drug Blowup

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 23.7% to $5.89 at 4:34 p.m.

ECYT Price Chart

ECYT Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer on the Problem With the Case for More Rate Hikes

Jim Cramer on the Problem With the Case for More Rate Hikes

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low